Pharma Executive Charged With Trading on Secret FDA News

George Demos, former drug safety official at Acadia Pharmaceuticals, faces federal charges for trading company stock based on confidential information about a negative FDA decision. The SEC alleges he violated securities laws. In pharma, regulatory approvals or rejections can swing stock prices dramatically — giving insiders who know the outcome in advance a significant trading advantage.